Mazen Nasrallah is a Rheumatology/Immunology physician. OpenAlex indexes 42 publications with 672 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit Street
Bullfinch
Boston, MA 02114
Telephone
617-726-3165Registry record last updated 23 Jul 2018.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.3%Folate Analog Metabolic Inhibitor26.4%Methotrexate84%Methotrexate Sodium16%Part D<11 patientsTNF inhibitor10.6%Humira(Cf) Pen69%Enbrel Sureclick12%Humira Pen11%Simponi9%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
19.5%Corticosteroid16.2%Prednisone100%Part D≥75 patientsAntidiarrheal microorganisms2.2%Folic Acid100%Part D≥13 patients+ 1 more class in this area
Antiparasitic
14%Antimalarial14%Hydroxychloroquine Sulfate100%Part D≥62 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Real-World Analysis of Clinical Prognostic Factors Influencing Survival in Patients with High-Grade Glioma (HGG) Receiving Radiotherapy (RT)
International Journal of Radiation Oncology*Biology*Physics
2025 - Clinical and Dosimetric Predictors of Severe Radiation-Induced Lymphopenia in Patients with Newly Diagnosed IDH-Wildtype High Grade Glioma Undergoing Adjuvant Radiotherapy
International Journal of Radiation Oncology*Biology*Physics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”